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ABSTRACT 
 
Background: Statins are among the most widely prescribed medications worldwide 
and usually many individuals involved in clinical and population studies are on statin 
therapy. Immunoglobulin G (IgG) glycosylation has been associated with numerous 
cardiometabolic risk factors.  
 
Methods: The aim of this study was to investigate the possible association of statin 
use with N-glycosylation of IgG. The association was analyzed in two large 
population cohorts (TwinsUK and KORA) using hydrophilic interaction liquid 
chromatography (HILIC-UPLC) in the TwinsUK cohort and reverse phase liquid 
chromatography coupled with electrospray mass spectrometry (LC-ESI-MS) in the 
KORA cohort. Afterwards we investigated the same association for only one statin 
(rosuvastatin) in a subset of individuals from the randomized double-blind placebo-
controlled JUPITER study using LC-ESI-MS for IgG glycome and HILIC-UPLC for total 
plasma N-glycome. 
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Results: In the TwinsUK population, the use of statins was associated with higher 
levels of core-fucosylated biantennary glycan structure with bisecting N-
acetylglucosamine (FA2B) and lower levels of core-fucosylated biantennary 
digalactosylated monosialylated glycan structure (FA2G2S1). The association 
between statin use and FA2B was replicated in the KORA cohort. In the JUPITER trial 
we found no statistically significant differences between the randomly allocated 
placebo and rosuvastatin groups. 
 
Conclusions: In the TwinsUK and KORA cohorts, statin use was associated with a 
small increase of pro-inflammatory IgG glycan, although this finding was not 
confirmed in a subset of participants from the JUPITER trial. 
 
General Significance: Even if the association between IgG N-glycome and statins 
exists, it is not large enough to pose a problem for glycomic studies. 
 
Key words: N-glycosylation, immunoglobulin G, total plasma N-glycome, statin, 
rosuvastatin 
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Introduction 
 
Glycosylation is a complex, highly specific and regulated co- and post-
translational process that covalently links glycans (complex oligosaccharides) to 
proteins and lipids [1,2]. Structural variations in the attached glycans strongly affect 
structure and function of proteins. Nearly all human plasma proteins, with exception 
of albumin, are modified by glycans [3,4]. Structural differences in terminal glycan 
antennae is common and recent studies demonstrated significant variation in 
glycome composition both within and between individuals [5–7]. Glycosylation is not 
only age- and gender-specific but is also affected by many environmental factors 
such as smoking, diet and medication [6,8–10]. Furthermore, glycosylation patterns 
have been characterized in relation to cardiovascular disease risk [11,12]. In 
particular decrease in immunoglobulin G (IgG) galactosylation has been associated 
with adverse cardiometabolic risk factors, including: cholesterol, triglycerides, C-
reactive protein (CRP), HbA1c, insulin, glucose, body mass index (BMI) and kidney 
disease [13–15]. 
 
Statins, also known as HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) 
reductase inhibitors, are among the most widely prescribed medications in the 
world. They are first-line drugs in the treatment of hypercholesterolemia and for 
cardiovascular prevention due to their efficacy in lowering LDL-cholesterol and 
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reducing cardiovascular morbidity and mortality [16,17]. However, more recent 
experimental and clinical investigations have revealed that statins are also potent 
anti-inflammatory agents that exert beneficial effects beyond LDL-cholesterol 
reduction [18,19].  
 
Both glycans and statins are connected with inflammation processes. 
Glycosylation is changing in many inflammatory diseases [20] and minor changes in 
glycan composition can have a profound influence on IgG effector functions by 
modulating binding to Fc receptors, and can convert IgG from a pro-inflammatory 
into an anti-inflammatory agent [21–23]. Moreover, it has been shown that use of 
statins is associated with expression of some glycosyltransferases in leukocytes and 
the expression of those glycosyltransferases was also changed in coronary syndrome 
patients [12]. Furthermore, many individuals involved in clinical and population 
studies are on statin therapy. If use of statins influences glycome composition, it 
could bias the results of glycomic studies. Therfore, it would be biologically and 
clinically relevant to know how statins relate to IgG glycomes. In this study we 
analyzed the association of statins with N-glycosylation of IgG in two large 
population cohorts (TwinsUK and KORA). Afterwards we investigated the same 
association for only one statin (rosuvastatin) in a subset of samples from the 
randomized double-blind placebo-controlled JUPITER study. 
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Material and methods 
 
Study Subjects 
 
This study was based on plasma samples obtained from three cohorts - the 
TwinsUK, the KORA and the JUPITER study. The demographic characteristics of the 
study populations are presented in Table 1. Written informed consent was obtained 
from all participants. 
 
TwinsUK registry is a national register of adult twins. Twins were recruited as 
volunteers by successive media campaigns without selecting for particular diseases 
or traits [24]. Statin drug status was gathered for 2247 individuals (328 cases and 
1919 controls) with glycan data available. Statins included atorvastatin, simvastatin, 
fluvastatin, pravastatin and rosuvastatin.  
 
German population study KORA F4 [25] (“Kooperative Gesundheitsforschung 
in der Region Augsburg”), included 1665 samples with statin drug status (257 cases 
and 1408 controls) and available glycan data. Statins included atorvastatin, 
simvastatin, fluvastatin, pravastatin and lovastatin. 
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Justification for the Use of Statins in Primary Prevention: An Intervention Trial 
Evaluating Rosuvastatin trial (JUPITER; www.ClinicalTrials.gov; NCT00239681) [19] 
was a double-blind, placebo-controlled trial that evaluated rosuvastatin 20 mg daily 
versus placebo in the primary prevention of first major CVD events in healthy men 
≥50 years and women ≥60 years with low-density lipoprotein cholesterol 
<130 mg/dL, but who were at increased risk of cardiovascular events on the basis of 
elevated high-sensitivity C-reactive protein (≥2 mg/L). 
 
IgG isolation 
 
Immunoglobulin G was isolated from plasma by affinity chromatography 
using 96-well protein G monolithic plates (BIA Separations, Ljubljana, Slovenia) as 
described previously [7]. Briefly, 100 µL of plasma was diluted 10× with PBS, filtered 
through 0.45 μm GHP filter plate (Pall Corporation, Ann Arbor, MI, USA), and then 
applied to the protein G plate and instantly washed. IgGs were eluted with 1 mL of 
0.1 M formic acid (Merck, Darmstadt, Germany) and immediately neutralized with 1 
M ammonium bicarbonate (Acros Organics, NJ, USA). 
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IgG N-glycans release and labeling  
 
Isolated IgG samples were dried in a vacuum centrifuge. After drying, 
proteins were denatured with addition of 30 μL 1.33% SDS (w/v) (Invitrogen, 
Carlsbad, CA, USA) and by incubation at 60 °C for 10 min. Subsequently, 10 μL of 4 % 
Igepal-CA630 (Sigma-Aldrich, St. Louis, MO, USA) and 1.25 mU PNGase F (ProZyme, 
Hayward, CA, USA) in 10 μL 5× PBS were added. The samples were incubated 
overnight at 37 °C for N-glycan release. The released N-glycans were labeled with 2-
aminobenzamide (2-AB). The labeling mixture was freshly prepared by dissolving 2-
AB (19.2 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) and 2-picoline borane (44.8 
mg/mL, Sigma-Aldrich, St. Louis, MO, USA) in DMSO (Sigma-Aldrich, St. Louis, MO, 
USA) and glacial acetic acid (Merck, Darmstadt, Germany) mixture (70:30, v/v). 25 μL 
of labeling mixture was added to each N-glycan sample in the 96-well plate and the 
plate was sealed using adhesive seal. Mixing was achieved by shaking for 10 min, 
followed by two hour incubation at 65 °C. Samples (in a volume of 75 μL) were 
brought to 80% ACN (v/v) by adding 300 μL of ACN (J.T. Baker, Phillipsburg, NJ, USA). 
Free label and reducing agent were removed from the samples using HILIC-SPE. 200 
μL of 0.1 g/mL suspension of microcrystalline cellulose (Merck, Darmstadt, Germany) 
in water was applied to each well of a 0.45 μm GHP filter plate (Pall Corporation, Ann 
Arbor, MI, USA). Solvent was removed by application of vacuum using a vacuum 
manifold (Millipore Corporation, Billerica, MA, USA). All wells were prewashed using 
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5× 200 μL water, followed by equilibration using 3× 200 μL acetonitrile/water (80:20, 
v/v). The samples were loaded to the wells. The wells were subsequently washed 7× 
using 200 μL acetonitrile/water (80:20, v/v). Glycans were eluted 2× with 100 μL of 
water and combined eluates were stored at −20 °C until usage. 
 
Total plasma proteins N-glycans release and labeling 
 
Total plasma proteins glycans were prepared in the same way as the IgG 
glycans. The only difference is that, instead with dried IgG eluate, the preparation 
begun with 10 μl of blood plasma and with addition of 20 μL 2 % SDS (w/v) 
(Invitrogen, Carlsbad, CA, USA) to each sample before the incubation at 65 °C for 10 
min. 
 
Hydrophilic Interaction Chromatography (HILIC)-UPLC 
 
Fluorescently labeled N-glycans were separated by hydrophilic interaction 
chromatography on Waters Acquity ultra-performance liquid chromatography 
(UPLC) instrument (Milford, MA, USA) consisting of a quaternary solvent manager, 
sample manager and a FLR fluorescence detector set with excitation and emission 
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wavelengths of 250 and 428 nm, respectively. The instrument was under the control 
of Empower 2 software, build 2145 (Waters, Milford, MA, USA). Labeled N-glycans 
were separated on a Waters bridged ethylene hybrid (BEH) Glycan chromatography 
column, 100 × 2.1 mm i.d. for IgG glycans and 150 × 2.1 mm i.d. for total plasma 
proteins glycans, 1.7 μm BEH particles, with 100 mM ammonium formate, pH 4.4, as 
solvent A and acetonitrile as solvent B. The separation method used a linear gradient 
of of 75-62% acetonitrile (v/v) at flow rate of 0.4 ml/min in a 25 min analytical run 
for IgG glycans and linear gradient of 70-53 % acetonitrile (v/v) at flow rate of 0.561 
ml/min in a 24.81 min analytical run for total plasma proteins glycans. The 
separation temperature was 60°C for IgG glycans and 25°C for total plasma proteins 
glycans. Samples were maintained at 10 °C before injection. Data processing was 
performed using an automatic processing method with a traditional integration 
algorithm after which each chromatogram was manually corrected to maintain the 
same intervals of integration for all the samples. The chromatograms were all 
separated in the same manner into 24 peaks (GP1-24) for IgG glycans and 46 peaks 
(GP1-46) for total plasma proteins glycans and the amount of glycans in each peak 
was expressed as % of total integrated area. The system was calibrated using an 
external standard of hydrolyzed and 2-AB labeled glucose oligomers from which the 
retention times for the individual glycans were converted to glucose units [26]. 
Glycans were analyzed on the basis of their elution positions and measured in 
glucose units then compared to reference values in the “Glyco-Base” database 
(available at: http://glycobase.nibrt.ie) for structure assignment [27]. For IgG 
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glycans, in addition to 24 directly measured glycan traits, 52 derived traits were 
calculated. These derived traits average particular glycosylation features 
(galactosylation, fucosylation, bisecting GlcNAc, and sialylation) (Supplementary 
Table 1). 
 
IgG tryptic digestion and purification 
 
25 µg IgG was digested with 200 ng of trypsin at 37°C (Worthington, USA) 
overnight. Resulting tryptic glycopeptides were purified by reverse phase solid phase 
extraction using Chromabond C18ec beads (Marcherey-Nagel, Germany). C18 beads 
were activated with 80% ACN containing 0.1% trifluoroacetic acid (TFA) (Sigma-
Aldich, USA) and conditioned with 0.1% TFA. Tryptic digests were diluted 10X with 
0.1% TFA, loaded onto C18 beads, washed with 0.1% TFA and finally eluted with 20% 
ACN containing 0.1% TFA. Eluates containing tryptic glycopeptides were dried by 
vacuum centrifugation and dissolved with 20 µL of ultrapure water. 
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LC-ESI-MS/MS analysis of IgG tryptic glycopeptides 
 
Tryptic digests were analyzed on nanoACUITY UPLC system (Waters, USA) 
coupled to micrOTOF-Q mass spectrometer (BrukerDaltonics, Bremen, Germany). 9 
µL of eluates containing IgG tryptic glycopeptides was loaded into Acclaim 
PepMap100 C8 (5mm×300 μm i.d.) trap column and washed 1 min with 0.1% TFA 
(solvent A) at a flow rate of 40 µL/min. Separation was achieved on a Halo C18 nano-
LC column (150mm×75 μm i.d., 2.7 μm HALO fused core particles) (Advanced 
Materials technology, USA) using a 3.5 min gradient at a flow rate of 1 µL/min from 
18% to 25% solvent B (80% ACN). Column temperature was 30°C. Mass spectra were 
recorded from m/z 200 to 1900 with 2 averages at a frequency of 0,5 Hz. 
Quadrupole ion energy and collision energy of the MS were set at 4 eV. NanoACUITY 
UPLC system and the Bruker micrOTOF-Q were operated under HyStar software, 
version 3.2. In Caucasian populations, IgG2 and IgG3 tryptic Fc glycopeptides have 
identical peptide moieties and are therefore not distinguishable by this profiling 
method [28]. Data were extracted using an in-house Python script. Briefly, data were 
m/z recalibrated using a subset of hand-picked analytes having a high signal-to-noise 
ratio and the expected isotopic distribution. After recalibration, intensities for top 
four isopotologes were extracted using 10 ppm m/z window. Based on top signals, 
retention times were aligned towards the cohort median. After defining retention 
time bins for analytes of interest, all of the signals belonging to a single analyte for 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
 
14 
 
 
 
 
every sample were summed up. In Caucasian populations, IgG2 and IgG3 have 
identical peptide moieties (E293EQFNSTFR301) of their tryptic Fc glycopeptides and 
were, therefore, not distinguished by the profiling method [23]. For statistical 
analysis we used the most prominent 20 glycopeptides that were present in 
subclasses IgG1 and IgG2/3 and the most prominent 10 glycopeptides that were 
present in IgG4. Derived traits that represent common biologically meaningful 
features (fucosylation, bisection, agalactosylation, monogalactosylation, 
digalactosylation and sialylation) shared among several measured glycans were 
calculated for each subclass group as described previously [29] (Supplementary 
Table 1). 
 
Statistical Analysis 
 
Statistical analysis was carried out using Stata version 12 and R (version 3.1.2) 
and visualized using the ggplot2 package. 
 
Glycans were globally normalized and log transformed to account for the 
right-skewness of their distributions. To remove experimental biases, all 
measurements were adjusted for batch and run-day effects using ComBat (R-
package sva). Derived glycan traits were calculated using normalized and batch-
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corrected glycan measurements (exponential of batch corrected measurements). All 
variables were centered and scaled to have mean 0 and standard deviation 1. 
Outliers (more than 6SD from the mean) were excluded from the analysis. 
 
Association analyses between statin use and glycan traits were performed 
using linear mixed regressions adjusting for age, sex, BMI in KORA cohort, and in the 
TwinsUK cohort, with additional adjustment for family relatedness as random effect. 
We used Bonferroni correction to account for multiple testing in the TwinsUK cohort 
(P=0.05/77≈6x10-4).  
 
For the TwinsUK cohort, the Bonferroni-significant associations between 
statins and glycans were replicated in the previously excluded group of MZ 
discordant twins using the same model. If the regression coefficients were the same 
direction in both analyses, the results were combined using inverse-variance fixed 
effect meta-analysis. 
 
For the JUPITER study the differences were calculated between glycan values 
after and before the randomized allocation of placebo or rosuvastatin. Differences 
between the placebo and rosuvastatin groups were tested using the Mann Whitney 
U test.
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Results 
 
Association of statins with IgG glycome in the TwinsUK cohort 
 
IgG glycome composition and information about the use of statins was 
available for 2247 individuals from the TwinsUK cohort. The demographic 
characteristics of the study population are summarized in Table 1. Released and 2-
AB labeled IgG glycans were analyzed by HILIC-UPLC. Chromatograms obtained for 
IgG glycans were separated in 24 glycan peaks, which correspond to different glycan 
structures (GP1-24, Figure 1). In addition to 24 directly measured glycan traits, 53 
derived traits were calculated as described previously [7] (Supplementary Table 1). 
These derived traits represent common biologically meaningful features 
(fucosylation, bisection, agalactosylation, monogalactosylation, digalactosylation, 
sialylation, etc.) shared among several measured glycans. 
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Table 1. The demographic characteristics of the study populations 
 
 
TwinsUK 
KORA JUPITER No Discordant 
Twins (n=2181) 
MZ Discordant 
Twins (n=66) 
No 
statins 
Statins 
No 
statins 
Statins 
No 
Statins 
Statins Placebo Rosuvastatin 
N 1886 295 33 33 1408 257 47 50 
Age 
(years)a 
55 
(±12) 
63 (±8) 
62 
(±10) 
62 
(±10) 
60 (± 9) 65 (±7) 67 (±5) 68 (±9) 
Sex (% 
Female) 
93% 90% 94% 94% 54% 43% 51% 50% 
BMI 
(Kg/m2)a 
26.5 
(±4.8) 
28.0 
(±5.8) 
27.6 
(±5.4) 
27.3 
(±5.0) 
28.0 
(±4.8) 
29.3 
 (±4.9) 
27.8 
(±4.6) 
29.9 
 (±5.6) 
Type 2 
DM, N 
28 27 2 3 97 52 1 0 
 
a Values are expressed as mean and standard deviation (in brackets) 
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To find associations between statins use and IgG glycan traits, we performed 
linear regression analysis in the population excluding monozygotic (MZ) discordant 
twins. We then validated Bonferroni significant glycans in MZ twin pairs discordant 
for statins use. If the regression coefficients were in the same direction in both 
analyses, we combined the results using inverse-variance fixed effect meta-analysis. 
Table 2 presents the list of glycans significantly associated with statins use in the 
discovery cohort, the validation results in the MZ discordant cohort and the meta-
analysis results. The use of statins was associated with a small increase in GP6 and 
GP6n, which contain core-fucosylated biantennary glycan structure with bisecting N-
acetylglucosamine (FA2B), together with biantennary monogalactosylated glycan 
structure (A2G1) in a much smaller amount, and a small decrease in GP18, which 
contains core-fucosylated biantennary digalactosylated monosialylated glycan 
structure (FA2G2S1), together with biantennary digalactosylated monosialylated 
glycan structure with bisecting N-acetylglucosamine (A2BG2S1) in a much smaller 
amount [7].
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Table 2. IgG glycan traits significantly associated with statin use in the TwinsUK cohort (P<6x10-4) and replicated in the KORA cohort (P<0.05) 
Glycan trait 
TwinsUK KORA 
Discovery MZ discordant Fixed effect meta-analysis IgG1 IgG2/3 IgG4 
Beta
e 
SE
f 
P value Beta
e
 SE
f
 P value Beta
e
 [95%CI
g
] P value Beta
e
 SE
f
 P value Beta
e
 SE
f
 P value Beta
e
 SE
f
 P value 
% of FA2B
d
 glycan 
in total IgG glycans
a 
 
0.036 0.009 4.26E-05 0.013 0.02 0.509 0.032 [0.02, 0.05] 5.50E-05 0.039 0.014 7.23E-03 0.039 0.014 6.55E-03 0.041 0.014 4.93E-03 
% of FA2B
d
 glycan 
in neutral IgG glycans
b 
0.029 0.007 1.06E-04 0.013 0.017 0.438 0.026 [0.013, 0.04] 1.00E-04 0.031 0.015 3.60E-02 0.034 0.015 2.08E-02 0.038 0.015 9.19E-03 
% of FA2G2S1
d
 glycan 
in total IgG glycans
c 
 
-0.031 0.009 3.39E-04 -0.267 0.02 0.189 -0.07 [-0.08, -0.05] 5.30E-18 not significant not significant not significant 
 
a Corresponds to the main structure in GP6 in HILIC-UPLC measurement 
b Corresponds to the main structure in GP6n in HILIC-UPLC measurement 
c Corresponds to the main structure in GP18 in HILIC-UPLC measurement 
d 
d 
d 
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d Structure abbreviations: all N-glycans have core sugar sequence consisting of two N-acetylglucosamines (GlcNAc) and three mannose residues; 
F indicates a core fucose α1–6 linked to the inner GlcNAc; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, biantennary glycan with 
both GlcNAcs as β1–2 linked; B, bisecting GlcNAc linked β1–4 to β1–3 mannose; Gx, number of β1–4 linked galactose (G) on antenna; Sx, 
number (×) of sialic acids linked to galactose. Structural schemes: blue square, N-acetylglucosamine; red triangle, fucose; green circle, mannose; 
yellow circle, galactose; purple diamond, N-acetylneuraminic acid 
e Regression Coefficient 
f Standard Error 
g Confidence Interval
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 We also explored the association between individual statin use and IgG 
glycan traits for simvastatin (111 cases vs. 1919 controls) and atorvastatin (93 cases 
vs. 1919 controls) in the TwinsUK cohort. Association analysis was performed using 
linear mixed regressions analysis adjusting for age, sex, BMI and family relatedness 
as random effect. Although 31 glycan traits were nominally significantly associated 
with simvastatin use (including GP6, GP6n and GP18 with regression coefficients in 
the same direction as found for all statins together), none of them remained 
significant after correction for multiple testing (Supplementary Table 2). For 
atorvastatin no associations were found (Supplementary Table 2). 
 
Replication in the KORA cohort 
 
We aimed to replicate the associations found in the TwinsUK population in 
1665 individuals from KORA cohort (257 cases and 1408 controls, Table 1). IgG Fc 
tryptic N-glycopeptides were measured by LC-ESI-MS, which enables glycosylation 
measurement of IgG Fc region at subclass-specific level. Linear regressions were 
applied to study the previously found significant associations between the use of 
statins and the glycan traits. Nominally statistically significant associations have been 
confirmed for two of three glycan traits (confirmed for FA2B in total and neutral IgG 
glycans, not confirmed for FA2G2S1) for each IgG subclass (IgG1, IgG2/3, IgG4) (Table 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
 
22 
 
 
 
 
2). The regression coefficients were in the same direction, and of similar magnitude 
as found in the TwinsUK population. 
 
Association of rosuvastatin with IgG Fc N-glycopeptides and total plasma proteins N-
glycome in the JUPITER study 
 
JUPITER is a randomized double-blind placebo-controlled study investigating 
the use of rosuvastatin versus placebo in the primary prevention of cardiovascular 
disease [19]. In a subset of JUPITER, we examined the effect of one year of 
rosuvastatin 20mg/day on the glycosylation of IgG Fc region at subclass-specific level 
(analysis of IgG tryptic glycopeptides by LC-ESI-MS). The analysis was performed on 
97 individuals - 47 on placebo and 50 on rosuvastatin (three individuals in the 
placebo group were excluded from the analysis because of low signal intensity) 
(Table 1). Derived traits that represent common biologically meaningful features 
(fucosylation, bisection, agalactosylation, monogalactosylation, digalactosylation and 
sialylation) shared among several measured glycans were calculated for each 
subclass group as described previously [29] (Supplementary Table 1). 
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We investigated the differences between the placebo and the rosuvastatin 
group (Supplementary Figure 1). For each derived trait of each IgG subclass (IgG1, 
IgG2/3, IgG4), differences were calculated between glycan values after and before 
the placebo/rosuvastatin treatment. We found no statistically significant differences 
between the two groups (Supplementary Table 3). We also tried to replicate the 
associations found in the TwinsUK population (for glycan traits corresponding to 
FA2B and FA2G2S1). However, treatment with rosuvastatin had no effect on these 
glycan traits in any of the IgG subclasses. 
 
To determine whether rosuvastatin induces a more general change in 
glycosylation of multiple proteins, we searched for associations between N-glycome 
of total plasma proteins (46 glycan peaks of enzymatically released, 2-AB labeled N-
glycans obtained by HILIC-UPLC, Supplementary Figure 2) and the use of rosuvastatin 
in the same individuals from the JUPITER study (Supplementary Figure 3). We found 
no significant difference in N-glycosylation of plasma proteins between the studied 
groups (Supplementary Table 4). 
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Discussion 
 
The aim of this study was to investigate the possible association of statin use 
with N-glycosylation of IgG in the TwinsUK and KORA populations. Afterwards we 
investigated the same association for only one statin (rosuvastatin) in a subset of 
participants from the randomized double-blind placebo-controlled JUPITER study. 
 
In the TwinsUK population, three glycan traits (GP6, GP6n and GP18) were 
found to be significantly associated with statin use in the discovery cohort, and they 
remained significant after the meta-analysis of the results from the discovery cohort 
and the validation results from the MZ discordant cohort. The use of statins was 
associated with higher levels of GP6 and GP6n (which mostly contain core-
fucosylated biantennary glycan structure with bisecting N-acetylglucosamine - FA2B) 
and lower levels of GP18 (which mostly contains core-fucosylated biantennary 
digalactosylated monosialylated glycan structure - FA2G2S1). The association 
between statin use and FA2B was replicated in the KORA cohort. IgG Fc tryptic N-
glycopeptides with FA2B glycan were significantly associated with statin use for all 
three IgG subclasses (IgG1, IgG2/3 and IgG4), in both total and neutral glycans. The 
regression coefficients were in the same direction, and of similar magnitude as 
found in the TwinsUK population. The association between statin use and FA2G2S1 
glycopeptides did not reach statistical significance. 
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FA2B is one of the IgG’s agalactosylated glycans. Glycans that lack terminal 
galactose activate complement and make IgG pro-inflammatory [30–32]. Also, FA2B 
is one of three glycans that change considerably with age (along with FA2G2 and 
FA2BG2) and the combination of these three glycans can explain up to 58% of 
variance in chronological age [33].  FA2B is increasing with age, and it is also 
increasing in many different pathological conditions (e.g. autoimmune diseases 
[34,35], kidney disease [14]  and cancer [36]).  In contrast, FA2G2S1, the major 
sialylated glycan in IgG glycome, is decreasing with age [33], and it was also reported 
to be decreased in patients with systemic lupus erythematosus [34] and kidney 
disease [14]. Terminal α2,6-sialylation of IgG glycans decreases the ability of IgG to 
bind Fcγ receptors (FcγRs), which increases expression of inhibitory FcγRIIB and is 
anti-inflammatory [21,37]. However, these findings have not been confirmed in all 
studies [22,38,39]. Taken together, these suggest that a pro-inflammatory pattern of 
IgG glycan was found in association with statins in both the TwinUK and KORA 
studies.  
 
Glycosylation is known to be affected by factors such as: expression levels, 
localization and substrate affinities and specificities of the glyco-enzymes, as well as 
abundance and trafficking of glycoprotein substrates and activated sugar donors 
concentrations [40–43]. Therefore, the observed changes in N-glycan profiles may be 
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the result of slight alterations in the levels of glycosyltransferases and glycosidases, 
caused by statin use or some other underlying factor. 
 
Patients who take statins usually have dyslipidemia and other CVD risk 
factors. Hence, there is a possibility that the associations that we found could be due 
to the connection between the IgG glycans and the lipid profile or other potential 
confounders, which was previously reported in some studies [33,44]. Therefore, to 
test whether the associations found between statin use and IgG glycosylation are the 
consequence of the direct influence of statin therapy, we investigated this 
association for randomly allocated rosuvastatin therapy versus placebo in the 
JUPITER trial. We found no statistically significant differences between the placebo 
and rosuvastatin groups after one year on study treatment. We also analyzed 
association between total plasma proteins N-glycome and rosuvastatin in the same 
individuals from the JUPITER study to determine whether rosuvastatin induces a 
more general change in glycosylation of multiple proteins. We found no difference in 
plasma glycosylation.  
 
When we explored the association between individual statin use and IgG 
glycan traits in the TwinsUK cohort for simvastatin and atorvastatin, we found 31 
nominally significantly associated glycan traits with simvastatin use and no glycan 
traits associated with atorvastatin use (Supplementary Table 2). Although none of 
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them remained significant after correction for multiple testing, the number of cases 
was too small (≈100) to detect a small effect size. Therefore, there is an indication 
that different statins may differently influence IgG N-gycome and that could be the 
reason we did not find any associations between rosuvastatin and IgG glycan traits. 
Another explanation might be that the association between statin use and IgG 
glycans we found in the TwinsUK and KORA cohorts was confounded by the lipid 
profile or other CVD risk factors, which drove the pro-inflammatory changes that we 
saw, and that those effects were eliminated in the randomized double-blind 
placebo-controlled JUPITER study. 
 
Conclusion 
 
In the TwinsUK and KORA cohorts, statin use was associated with a small 
increase of pro-inflammatory IgG glycan, although this finding was not confirmed in 
a subset of participants from the JUPITER trial. There are several possible 
explanations for this: (1) some statins, but not rosuvastatin, may influence the IgG 
glycome; (2) the association between statin use and IgG glycans may be confounded 
by the lipid profile or other indications for statin use (eg. CVD risk factors) which 
drove the pro-inflammatory changes that we saw in the TwinsUK and KORA cohorts 
but not in the randomized JUPITER study; (3) the number of individuals from the 
JUPITER that we included in the analysis was smaller than in other two cohorts (97 
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individuals from the JUPITER trial vs. 2247 individuals from the TwinsUK cohort and 
1665 individuals from the KORA cohort), hence lack of association might also be due 
to power issues or due to lack of signal in the JUPITER trial, which enrolled 
individuals who had evidence of low-grade chronic inflammation. Although we 
cannot give a definite answer to the question whether statins have any influence on 
the composition of the IgG glycans, we can conclude that the magnitude of their 
effect on IgG N-glycome is too small to confound associations with N-glycome 
observed in clinical or epidemiological studies. 
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Figure legends 
 
Figure 1. Chromatogram of 2-AB labeled N-linked glycans released from IgG and 
separated by HILIC-UPLC. The integration areas, together with glycan structures 
present in each peak are given. Peaks are numbered from GP1-GP24. 
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Supplementary files 
 
Supplementary Figure 1. The differences in derived IgG glycan traits (for each IgG 
subclass) between the placebo (red, 0) and the rosuvastatin (blue, 1) group. For each 
group there are two time points - before (left) and after (right) the 
placebo/rosuvastatin treatment. 
 
Supplementary Figure 2. Chromatogram of 2-AB labeled N-linked glycans released 
from total plasma proteins and separated by HILIC-UPLC. The integration areas, 
together with glycan structures present in each peak are given. Peaks are numbered 
from PGP1-PGP46. 
 
Supplementary Figure 3. . The differences in total plasma N-glycome (glycan peaks 
PGP1-46 obtained by HILIC-UPLC) between the placebo (red, 0) and the rosuvastatin 
(blue, 1) group. For each group there are two time points - before (left) and after 
(right) the placebo/rosuvastatin treatment. 
 
Supplementary Table 1. Description of IgG glycan traits (directly measured and 
derived traits) measured by HILIC-UPLC and LC-ESI-MS (with mass list). 
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Supplementary Table 2. Association analysis between individual statin use (for 
simvastatin and atorvastatin) and IgG glycan traits in the TwinsUK cohort . P values 
and regression coefficients (beta) were obtained from linear mixed regressions 
analysis adjusting for age, sex, BMI and family relatedness as random effect.  
 
Supplementary Table 3. P values for JUPITER study IgG glycans obtained from Mann 
Whitney U test.  For each glycan trait for each IgG subclass (IgG1, IgG2/3, IgG4) 
differences were calculated between glycan values after and before the 
placebo/rosuvastatin treatment and then the placebo and the rosuvastatin groups 
were compared. 
 
Supplementary Table 4. P values for JUPITER study total plasma N-glycans obtained 
from Mann Whitney U test.  For each glycan trait differences were calculated 
between glycan values after and before the placebo/rosuvastatin treatment and 
then the placebo and the rosuvastatin groups were compared. 
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Highlights 
 
 In the first cohort 3 glycan traits were significantly associated with statin 
use 
 2 of them were replicated in the second cohort 
 In a rosuvastatin clinical trial no significant differences were found 
 Statin use does not pose a problem for glycomic studies 
